JP2022523806A5 - - Google Patents
Info
- Publication number
- JP2022523806A5 JP2022523806A5 JP2021552582A JP2021552582A JP2022523806A5 JP 2022523806 A5 JP2022523806 A5 JP 2022523806A5 JP 2021552582 A JP2021552582 A JP 2021552582A JP 2021552582 A JP2021552582 A JP 2021552582A JP 2022523806 A5 JP2022523806 A5 JP 2022523806A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- cedna vector
- item
- pharmaceutical composition
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814477P | 2019-03-06 | 2019-03-06 | |
| US62/814,477 | 2019-03-06 | ||
| PCT/US2020/021367 WO2020181182A1 (en) | 2019-03-06 | 2020-03-06 | Closed-ended dna (cedna) and immune modulating compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523806A JP2022523806A (ja) | 2022-04-26 |
| JP2022523806A5 true JP2022523806A5 (https=) | 2023-03-14 |
Family
ID=72337625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552582A Pending JP2022523806A (ja) | 2019-03-06 | 2020-03-06 | 閉端ｄｎａ（ｃｅｄｎａ）および免疫調節化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220184231A1 (https=) |
| EP (1) | EP3934701A4 (https=) |
| JP (1) | JP2022523806A (https=) |
| AU (1) | AU2020231228A1 (https=) |
| CA (1) | CA3132164A1 (https=) |
| IL (1) | IL286031A (https=) |
| MA (1) | MA55223A (https=) |
| SG (1) | SG11202108864UA (https=) |
| WO (1) | WO2020181182A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ762100A (en) | 2017-08-09 | 2025-12-19 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| EP3833766A1 (en) | 2018-08-09 | 2021-06-16 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| JP2023535632A (ja) | 2020-07-27 | 2023-08-18 | アンジャリウム バイオサイエンシズ エージー | Ｄｎａ分子の組成物、その作製方法、及びその使用方法 |
| WO2025114932A1 (en) * | 2023-11-30 | 2025-06-05 | Sanofi | Purification of closed-ended dna molecules |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| CA2975371C (en) * | 2015-01-30 | 2024-02-13 | Nof Corporation | Cationic lipid for nucleic acid delivery |
| US10086089B2 (en) * | 2015-09-18 | 2018-10-02 | DNARx | Systems and methods for nucleic acid expression in vivo |
| GB2547179A (en) * | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
| MX2018010633A (es) * | 2016-03-03 | 2019-06-13 | Univ Massachusetts | Acido desoxirribonucleico (adn) lineal duplex de extremos cerrados para transferencia genica no viral. |
| CN117653654A (zh) * | 2016-11-23 | 2024-03-08 | 柏林制药股份有限公司 | 用于抑制和/或压制tlr9激活的适体 |
| WO2018237369A2 (en) * | 2017-06-23 | 2018-12-27 | Vical Incorporated | Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection |
-
2020
- 2020-03-06 MA MA055223A patent/MA55223A/fr unknown
- 2020-03-06 WO PCT/US2020/021367 patent/WO2020181182A1/en not_active Ceased
- 2020-03-06 CA CA3132164A patent/CA3132164A1/en active Pending
- 2020-03-06 US US17/435,419 patent/US20220184231A1/en active Pending
- 2020-03-06 SG SG11202108864UA patent/SG11202108864UA/en unknown
- 2020-03-06 JP JP2021552582A patent/JP2022523806A/ja active Pending
- 2020-03-06 EP EP20767207.2A patent/EP3934701A4/en active Pending
- 2020-03-06 AU AU2020231228A patent/AU2020231228A1/en active Pending
-
2021
- 2021-09-01 IL IL286031A patent/IL286031A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022523806A5 (https=) | ||
| US20190315642A1 (en) | Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome | |
| US10351452B2 (en) | Compositions for in vivo expression of therapeutic sequences in the microbiome | |
| US12281309B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| WO2022167009A1 (zh) | 靶向Aqp1 mRNA的sgRNA及其载体与应用 | |
| CA3119302A1 (en) | Synthetic immunomodulation with a crispr super-repressor in vivo | |
| KR102683896B1 (ko) | Gm-csf의 분비를 위한 발현벡터 및 이에 의해 형질전환된 항암 재조합 균주 | |
| WO2008053588A1 (en) | Cytokine production regulator gene and use thereof | |
| US12415850B2 (en) | Compositions and methods for regulating production of an antibody like protein and ribonucleic acid | |
| US12497618B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12264329B1 (en) | Composition for regulating production of fusion proteins | |
| CN106177993B (zh) | 传染性法氏囊病病毒dna疫苗及其构建方法 | |
| US12338452B1 (en) | Compositions for regulating production of an antibody like protein and ribonucleic acid | |
| US12522847B2 (en) | Plasmid encoding an insulin peptide and Fc fusion protein | |
| WO2015116531A1 (en) | Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses | |
| US12486506B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12516332B2 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12480121B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12534733B2 (en) | Composition for regulating production of interfering ribonucleic acid | |
| US12480129B1 (en) | Composition for regulating production of interfering ribonucleic acid | |
| CN101240292A (zh) | 人对氧磷酶3基因表达载体的构建及其应用 | |
| KR20250075514A (ko) | 단백질 번역 효율 향상용 mRNA 구조체 및 이의 용도 | |
| Ryan et al. | Gene therapy for the inner ear: challenges and promises |